Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of cancer"
DOI: 10.1016/j.ejca.2019.08.017
Abstract: BACKGROUND The fully human monoclonal antibody patritumab blocks HER3 activation, a resistance mechanism to cetuximab, induced by heregulin (HRG). A phase Ib study in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and… read more here.
Keywords: platinum; cetuximab; group; placebo ... See more keywords
Patritumab deruxtecan induces immunogenic cell death.
Sign Up to like & getrecommendations! Published in 2025 at "Oncoimmunology"
DOI: 10.1080/2162402x.2025.2514050
Abstract: ABSTRACT Antibody-drug conjugates (ADCs) enable targeted delivery of cytotoxic payload to cancer cells. Here, we characterized the mode of action of the ADC patritumab deruxtecan, which is a monoclonal antibody specific for Erb-B2 Receptor Tyrosine… read more here.
Keywords: cell death; patritumab; immunogenic cell; patritumab deruxtecan ... See more keywords